MMX mesalazine was well-tolerated 156 adverse events were observed in 72/312 patients 23.1%. There were 60 treatment-related adverse events in 27/312 patients 8.7% and nine serious adverse events of which one pancreatitis was considered to be related to treatment.
La mesalazina-MMX fue bien tolerada, observándose 156 acontecimientos adversos en 72/312 pacientes 23,1% 60 acontecimientos adversos relacionados con el tratamiento en 27/312 pacientes [8,7%]; 9 acontecimientos adversos graves, uno considerado como relacionado con el tratamiento [pancreatitis].